Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults

Estévez, Zurina Cinza; Betancourt, Arístides Aguilar; González, Verena Muzio; Baile, N. Figueroa; Silva, Carmen Valenzuela; Bernal, Francisco Hernández; Arias, Eduardo Pentón; Fernández, Aurora Delhanty; Olazábal, Nelia Martin; Martín, Amaurys del Río; Batista, Lester Leal; Ríos, Gloria Véliz; Hernández, Héctor Hernández y; Hernández, Aracelis Blanco; Lugo, Evelyn Pérez; Cruz, Joel de la Torre; Marchec, Bertha L. Batista; Falcón, Leovaldo Álvarez; Brito, Jannet Trujillo; León, Darién Ortega; Saura, Pedro López

doi:10.1016/j.biologicals.2006.06.001

Cited by 36 publications

(30 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…39 Factors historically related to reduced responsiveness to conventional hepatitis B vaccines include advanced age, male sex, obesity, smoking, alcohol, injection site and storage conditions, dosage and immunization schedules, cirrhosis, immune suppression, diabetes mellitus, chronic renal failure and genetically determined resistance, among others. [40][41][42][43][44][45][46] In the present study, female sex and BMI (non-obese) were the two demographic variables with a greater impact on higher seroprotection rates, which is in agreement with the results of other trials.…”

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tsupporting

confidence: 81%

Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults

Hernández-Bernal¹,

Aguilar-Betancourt²,

Aljovin³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

Section: ©2 0 1 1 L a N D E S B I O S C I E N C E D O N O T D I S Tsupporting

confidence: 81%

Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults

Hernández-Bernal¹,

Aguilar-Betancourt²,

Aljovin³

et al. 2011

Human Vaccines

View full text Add to dashboard Cite

“…20 After that, a large number of studies showed that antibody responses to hepatitis B vaccine were significantly reduced in obese individuals compared with those non-obese people. [21][22][23][24] Moreover, the study conducted by Dinelli et al reported that the obese women who did not response to 6 doses of recombinant hepatitis B vaccine, was seroconverted after weight reduction. 25 To further understand the impaired responses of HBV vaccination, we recently performed a meta-analysis to characterize the relationship between obesity and immune response to hepatitis B vaccine.…”

Section: Discussionmentioning

confidence: 99%

Influences of obesity on the immunogenicity of Hepatitis B vaccine

Liu¹,

Guo

Dong

2017

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

Objective: Hepatitis B vaccine is regarded as the most effective method for the prevention of hepatitis B virus (HBV) infection. However, several factors such as age, body mass index and immunocompetent state have been reported to be associated with reduced immunization responses. The present commentary was aimed to discuss the influences of obesity on the immunogenicity of hepatitis B vaccines. Data sources: Available peer-reviewed literatures, practice guidelines, and statistics published on hepatitis B vaccine in obesity between 1973 and 2015. Conclusions: Obesity was significantly associated with non-response to hepatitis B vaccine immunization. The risk of nonresponsiveness of hepatitis B vaccine among obese people increased with BMI. Moreover, the obesity might lead to an increased risk of HBV vaccine-escape mutations. The mechanism responsible for decreased immunization responses in obesity included leptininduced systemic and B cell intrinsic inflammation, impaired T cell responses and lymphocyte division and proliferation. Therefore, more studies should be performed to analyze the influences of obesity on the immunogenicity of hepatitis B vaccines to improve the immunoprotecive effect of hepatitis B vaccines in future.

show abstract

“…Although the Engerix-B ™ -vaccinated cohort (n=169) lacked the same statistical power as the Recombivax HB ™ cohort (n=426) [36], it was confirmed through later studies [37, 38] that obesity was related to a significant decline (p< 0.01, p= 0.015, respectively) in Engerix-B ™ vaccine-induced anti-HBs titers. Since then, several studies have included analyses that continue to identify obesity as a risk factor for diminished or non-protective anti-HBs titers over time [39–42]. …”

Section: Hepatitis B Virus (Hbv)mentioning

confidence: 99%

The weight of obesity on the human immune response to vaccination

Painter

Ovsyannikova

Poland

2015

Vaccine

167

130

View full text Add to dashboard Cite

Despite the high success of protection against several infectious diseases through effective vaccines, some sub-populations have been observed to respond poorly to vaccines, putting them at increased risk for vaccine-preventable diseases. In particular, the limited data concerning the effect of obesity on vaccine immunogenicity and efficacy suggests that obesity is a factor that increases the likelihood of a poor vaccine-induced immune response. Obesity occurs through the deposition of excess lipids into adipose tissue through the production of adipocytes, and is defined as a body-mass index (BMI) ≥ 30 kg/m2. The immune system is adversely affected by obesity, and these “immune consequences” raise concern for the lack of vaccine-induced immunity in the obese patient requiring discussion of how this sub-population might be better protected.

show abstract

Immunogenicity and safety assessment of the Cuban recombinant hepatitis B vaccine in healthy adults

Cited by 36 publications

References 23 publications

Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults

Comparison of four recombinant hepatitis B vaccines applied on an accelerated schedule in healthy adults

Influences of obesity on the immunogenicity of Hepatitis B vaccine

The weight of obesity on the human immune response to vaccination

Contact Info

Product

Resources

About